Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Welcome to McKesson's third quarter fiscal 2025 earnings conference call. Please be advised that today's conference is being ...

We recently compiled a list of the Jim Cramer Shed Light on These 8 Stocks Recently. In this article, we are going to take a ...

AbbVie (NYSE:ABBV – Get Free Report) had its price target upped by stock analysts at Guggenheim from $212.00 to $214.00 in a ...

AbbVie (NYSE:ABBV – Get Free Report) had its price target lifted by equities researchers at UBS Group from $181.00 to $190.00 in a note issued to investors on Monday,Benzinga reports. The brokerage ...

State leaders are reviving talk of importing prescription drugs from Canada, even as US drugmakers and health-care attorneys ...

Exxon Mobil CEO Darren Woods Says Yellowtail Project In Guyana Could Start By Q3 2025; Says Major Planned Projects For 2025 Could Begin Ahead Of Schedule Guidance is a report released by a public ...